anxiety/obesity

BACKGROUND Neurologic and neuropsychiatric disorders such as depression, anxiety, amyotrophic lateral sclerosis, and central nervous system injuries, to name a few, afflict millions of people every year and result in a multitude of symptoms including weight change, decreased energy, headaches,

The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals. Neuropeptide Y (NPY), first isolated

This invention relates generally to electrical stimulation therapy for medical disorders, more specifically to neuromodulation therapy for obesity, eating disorders, and anxiety disorders with an external pulse generator (stimulator) containing predetermined programs, and adapted to be used with an

BACKGROUND OF THE INVENTION The active ingredients of this invention include (1-[2-(dimethylamino)-1-(4-methoxyphenyl) ethyl] cyclohexanol), or therapeutically acceptable salts thereof, which are known generally as venlafaxine and its analogues. Venlafaxine is disclosed in U.S. Pat. No. 4,535,186

BACKGROUND OF THE INVENTION The present invention is generally directed to medical (and in many cases, more specifically to neurological) treatment devices, systems, and methods. In exemplary embodiments, the invention provides radiosurgical treatment methods and systems for directing ionizing

1. FIELD OF INVENTION The invention relates to optically pure derivatives of (-)-venlafaxine, methods of their synthesis, compositions comprising them, and methods of their use. 2. BACKGROUND OF THE INVENTION A number of nontricyclic antidepressants have recently been developed that diminish the

BACKGROUND OF THE INVENTION The present invention relates to indole derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The active compounds of the present invention are useful in treating migraine and other

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to pyrrole compounds substituted with i) a heteroaryl ring and ii) another heteroaryl or aryl ring with at least one of the rings being further substituted with another ring. In particular, this invention is

TECHNICAL FIELD The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual

TECHNICAL FIELD The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual

TECHNICAL FIELD The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual

CROSS-REFERENCE TO RELATED APPLICATIONS The present application is a 371 application of PCT/US2010/026626 filed Mar. 9, 2010, which claims priority benefit of U.S. provisional application Ser. No. 61/158,554, filed Mar. 9, 2009, each of which is incorporated by reference herein. FIELD OF THE

FIELD OF THE INVENTION The present invention relates to pyridone compounds which act as melanin concentrating hormone receptor-1 (MCHR1) antagonists, pharmaceutical compositions containing such compounds, and methods for using such compounds for the treatment of MCHR1 mediated diseases such as

CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority of the benefits of the filing of patent application Nos. PCT/EP2006/069830 (WO2007/071646) filed Dec. 18, 2006, and EPO Patent Application No. 05112616.7 filed Dec. 21, 2005. The complete disclosures of the aforementioned

CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority of the benefits of the filing of patent application Nos. EP06125421.5 filed Dec. 5, 2006, and PCT/EP2007/063310 filed Dec. 4, 2007. The disclosures of the aforementioned related patent applications are hereby incorporated